Cochrane Renal Group

 Back
autoid 65
crg_id CRG110500017
titleoftrial Intensive versus Conventional Renal Support in Acute Renal Failure
acronymnoftrial VA/NIH Acute Renal Failure Trial Network (ATN) Study
website http://www.ATNStudy.org
identificationno NCT00076219
leadprefix Dr
leadsurname Palevsky
leadgivennames Paul
leadposition Chief, Renal Section
leaddepartment Medical Service
leadorganisation VA Pittsburgh Healthcare System
leadaddress University Drive, Pittsburgh, PA 15240, USA
leademail palevsky@pitt.edu
leadphone +1 412 688 6474
leadfax +1 412 688 6908
leadsuffix
contactprefix
contactsurname
contactgivennames
contactposition
contactdepartment
contactorganisation
contactaddress
contactemail
contactphone
contactfax
funding govt
otherfunding
fundingnameofsponsors US Department of Veterans Affairs Cooperative Studies Program; NIH/NIDDK
ethicsapproval yes
studytype randomised
studytype_other
groupassignment parallel
blinding_patients no
blinding_investigators no
blinding_outcomes no
blinding_analysts yes
proposedstart
actualstart 11/2003
proposedcompletiondate 11/2007
actualcompletiondate
multi_center_study yes
numberofcentres 21-25
multi_national_study no
countrycentres USA
researchquestion To determine if a strategy of intensive renal support decreases 60-day all cause mortality in critically ill patients with acute renal failure as compared to conventional management of renal
replacement therapy.
study_status_recruitment ongoing
study_status_recruitment_follow ongoing
healthcarecondition Acute Renal Failure
intervention1 6-times per week hemodialysis in hemodynamically stable patients; 6-tiems per week SLED or CVVHDF with an effluent flow rate of 35 mL/kg/hour in hemodynamically unstable patients
intervention2 3-times per week hemodialysis in hemodynamically stable patients; 3-tiems per week SLED or CVVHDF with an effluent flow rate of 20 mL/kg/hour in hemodynamically unstable patients
intervention3
intervention4
participants_gender both
participants_other adults
age at least 18 years of age
totalrecruitment 1164
inclusion 1. ARF clinically consistent with a diagnosis of ATN, defined as: clinical setting of acute ischemic or nephrotoxic injury; and oliguria (average urine output < 20 mL/hr) for > 24 hours or an increase in serum creatinine of at least 2.0 mg/dL (men)/1.5 mg/dL (women) over a period of no more than 4 days
2. Plan for renal replacement therapy
3. Receiving care in critical care unit
4. At least one non-renal organ failure (SOFA organ system score of at least 2) or the presence of sepsis
5. Age of at least 18 years
6. Informed consent

exclusion 1. Baseline CKD defined by serum creatinine > 2 mg/dL (men) / 1.5 mg/dL (women)
2. ARF due to an etiology other than ATN
3. More than 72 hours since meeting BOTH of the following: Definition of ARF as specified in the inclusion criteria and a BUN > 100 mg/dL
4. More than 1 hemodialysis treatment or more than 24 hours of CRRT
5. History of kidney transplantation
6. Weight > 128.5 kg
7. Pregnancy
8. Prisoner
9. Non-candidacy for RRT
10. Not expected to survive 28-days due to underlying chronic medical condition
11. Moribund sate or CMO status
12. Participation in a concurrent interventional trial
13. Patient refusal
14. Physician refusal
primaryoutcomes 60-day all cause mortality
secondaryoutcomes Hospital mortality
1-year mortality
Recovery of renal function by day 28
Cost effectiveness

Exploratory outcomes
Duration of renal support
ICU length-of-stay
Hospital length-of-stay
Discharge to ?home? off of dialysis by day-60
SOFA Organ Failure Scores at days 1-14, 21and 28
reference 1. Palevsky PM, O\'Connor T, Zhang JH, Star RA, Smith MW for the VA/NIH Acute Renal Failure Trial Network. Design of the VA/NIH Acute Renal Failure Trial Network (ATN) study: Intensive versus conventional renal support in acute renal failure. Clinical Trials 2005; 2:423-435.